Drug Profile
Research programme: psoriasis therapies - Teva Pharmaceutical Industries
Alternative Names: TV-3813Latest Information Update: 29 Mar 2011
Price :
$50
*
At a glance
- Originator Weizmann Institute of Science
- Developer Teva Pharmaceutical Industries
- Class Alcohols
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 29 Mar 2011 No development reported - Preclinical for Psoriasis in Israel (Topical)
- 25 Feb 2008 Preclinical development is ongoing
- 28 Jun 2006 Preclinical trials in Psoriasis in Israel (Topical)